MediciNova, Inc.
NASDAQ:MNOVBiotechnology
-$0.02 today
- Market cap
- $68.14M
- Beta
- 0.62
- P/E (TTM)
- -5.6
- EPS (TTM)
- -$0.24
Volume 0.12M
Average 0.04M
MNOV Net Change in Cash
Combined operating, investing, financing, and currency effects on the cash balance during the period.
MediciNova, Inc.NASDAQ: MNOV
Net Change in Cash · Q1 FY2026 · quarter ended Mar 2026
Net change in cash declines year over year
Q1 FY2026 net change in cash of $3.48M (cash outflow) fell 8.2% year over year, ahead of the -12.5% change in trailing-twelve-month net change in cash. Sequentially, it rose 98.0% from the prior quarter. Over 3 fiscal years it compounded at -43.5% a year.
Context
- Net change in cash amounted to 2332.0% of revenue in FY2025.
- Net change in cash increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth of -8.2% holds above the trailing-twelve-month pace of -12.5%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Net Change in Cash history
USD · from the cash flow
- Latest · FY2025
- (9.55M) USD
- Year-over-year change
- +10.2%
| Period | Period end | Net Change in Cash | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (9.55M) | +10.2% |
| FY2024 | 2024-12-31 | (10.64M) | -132.7% |
| FY2023 | 2023-12-31 | 32.49M | +161.4% |
| FY2022 | 2022-12-31 | (52.93M) | -564.5% |
| FY2021 | 2021-12-31 | 11.39M | — |
Net Change in Cash vs competitors
How MNOV compares with its peers on the latest reported figures
- MNOV's LTM Mar 2026 net change in cash of $9.24M is the 7th largest of the 11 companies compared; the peer median is $7.68M.
- Its year-over-year change of -12.5% is the 8th highest of 11, against a peer median of +208.0%.
- Net change in cash amounts to 1549.0% of revenue for MNOV, versus a peer median of 202.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $172.33M | +307.6% | — | — | |
| LTM Mar 2026 | $164.5M | +2347.2% | — | 248.6% | |
| LTM Mar 2026 | $40.44M | -10.4% | -16.1% | — | |
| LTM Mar 2026 | $26.05M | -291.6% | -14.0% | 285.1% | |
| LTM Mar 2026 | $22.05M | +1023.2% | — | 8.6% | |
| LTM Mar 2026 | $12.21M | -526.2% | -64.4% | — | |
| LTM Mar 2026 | $9.24M | -12.5% | -43.5% | 1549.0% | |
| LTM Mar 2026 | $9.2M | +108.4% | -58.2% | — | |
| LTM Mar 2026 | $8.63M | +4755.2% | -79.0% | — | |
CBUSCibus, Inc. | LTM Mar 2026 | $6.74M | +832.4% | -25.5% | 157.2% |
ACRVAcrivon Therapeutics, Inc. Common Stock | LTM Mar 2026 | $5.09M | -135.0% | — | — |
| Peer median (excluding MNOV) | $7.68M | +208.0% | -41.8% | 202.9% | |
Competitors are the stored peer set for MNOV. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (10.13M) | (14.07M) | (8.57M) | (11.05M) | (12M) |
| Depreciation & Amortization | 26.15K | 17.71K | 20.3K | 21.08K | 20.1K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 1.72M | 642.52K | 710.71K | 1.19M | 829.1K |
| Change in Working Capital | (1.21M) | 334.1K | 111.99K | (979.56K) | 1.17M |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | (1.03M) | 329.01K | 19.24K | (312.35K) | 459.87K |
| Other Working Capital | (181.42K) | 5.09K | 92.75K | (667.21K) | 705.15K |
| Other Non-Cash Items | 216.93K | 163.19K | 297.49K | 173.32K | 173.68K |
| Operating Cash Flow | (9.38M) | (12.91M) | (7.43M) | (10.64M) | (9.81M) |
| Capital Expenditures | (28.73K) | (5.01K) | (21.3K) | (895) | 0 |
| Acquisitions (Net) | 0 | 5.01M | 0 | 0 | 0 |
| Purchases of Investments | 0 | (59.88M) | 0 | 0 | 0 |
| Sales of Investments | 0 | 19.88M | 39.93M | 0 | 0 |
| Other Investing Activities | 0 | (5.01M) | 0 | 198 | (2.9K) |
| Investing Cash Flow | (28.73K) | (40.01M) | 39.91M | (697) | (2.9K) |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 20.89M | 7.92K | 0 | 0 | 0 |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (112.26K) | 0 | 0 | 0 | 244.02K |
| Financing Cash Flow | 20.78M | 7.92K | 0 | 0 | 244.02K |
| Effect of Forex Changes | 26.55K | (16.81K) | 17.27K | 3.96K | 15.68K |
| Net Change in Cash | 11.39M | (52.93M) | 32.49M | (10.64M) | (9.55M) |
| Free Cash Flow | (9.41M) | (12.92M) | (7.45M) | (10.64M) | (9.81M) |
MediciNova, Inc.
NASDAQ:MNOV
Intrinsic Alpha fair value
Locked
Current Price
$1.33
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.